文献速递临床试验与 GCP基础与转化研究组学、生物样本库与精准医学

益生元补充剂对肥胖合并膝骨关节炎成人膝关节功能、肠道菌群和炎症影响的随机对照试验方案

Effect of a prebiotic supplement on knee joint function, gut microbiota, and inflammation in adults with co-morbid obesity and knee osteoarthritis: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-04-07

这是一项双盲、安慰剂对照、随机试验方案,计划招募60名BMI>30 kg/m2且Kellgren-Lawrence II-III级膝骨关节炎成人,随机接受益生元(富含低聚果糖的菊粉,16 g/天)或热量匹配安慰剂(麦芽糊精)6个月,评估膝关节功能、疼痛、血清炎症标志物、代谢组学、生活质量和肠道菌群。该试验旨在首次提供益生元补充对肥胖合并膝骨关节炎成人疗效的人体证据。

要点

  • 益生元补充可能通过改善肠道菌群减轻系统性炎症,从而改善肥胖合并膝骨关节炎成人的膝关节功能和疼痛。
  • 试验采用双盲、安慰剂对照、随机设计,干预6个月,随访至停用后3个月。
  • 主要评估包括膝关节功能、疼痛、血清炎症标志物、代谢组学、生活质量和肠道菌群。

核心结论

  • 该试验将首次提供益生元补充对肥胖合并膝骨关节炎成人膝关节功能、疼痛及肠道菌群影响的人体证据。

研究设计与样本

  • 双盲、安慰剂对照、随机试验,计划招募60名BMI>30 kg/m2且Kellgren-Lawrence II-III级膝骨关节炎成人。
  • 参与者按性别、BMI和年龄分层随机,接受益生元(富含低聚果糖的菊粉,16 g/天)或热量匹配安慰剂(麦芽糊精)6个月。
  • 在基线、3个月、6个月(干预结束)和干预结束后3个月评估结局。

关键数值与推荐

  • 纳入标准:BMI>30 kg/m2,Kellgren-Lawrence grade II-III膝骨关节炎。
  • 干预:益生元组为富含低聚果糖的菊粉16 g/天,安慰剂组为热量匹配的麦芽糊精,持续6个月。
  • 评估指标包括人体测量、基于表现的功能测试、膝关节疼痛、血清炎症标志物和代谢组学、生活质量及肠道菌群。

临床怎么用

  • 若试验成功,益生元补充可能成为简单、安全、易坚持的干预措施,用于减轻肥胖合并膝骨关节炎成人的膝关节疼痛并改善生活质量。
  • 该保守干预有潜力延迟或避免全关节置换的需求,减轻医疗系统压力。

局限性

  • 原文未报告研究结果,无法评估益生元补充的实际疗效和安全性。
  • 样本量60人,可能影响统计效能和结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteoarthritis (OA) is a chronic and painful condition where the articular cartilage surfaces progressively degenerate, resulting in loss of function and progressive disability. Obesity is a primary risk factor for the development and progression of knee OA, defined as the "metabolic OA" phenotype. Metabolic OA is associated with increased fat deposits that release inflammatory cytokines/adipokines, thereby resulting in systemic inflammation which can contribute to cartilage degeneration. There is currently no cure for OA. Prebiotics are a type of dietary fiber that can positively influence gut microbiota thereby reducing systemic inflammation and offering protection of joint integrity in rodents. However, no human clinical trials have tested the effects of prebiotics in adults with obesity suffering from knee OA. Therefore, the purpose of this double-blind, placebo-controlled, randomized trial is to determine if prebiotic supplementation can, through positive changes in the gut microbiota, improve knee function and physical performance in adults with obesity and knee OA. METHODS: Adults (n = 60) with co-morbid obesity (BMI > 30 kg/m2) and knee OA (Kellgren-Lawrence grade II-III) will be recruited from the Alberta Hip and Knee Clinic and the Rocky Mountain Health Clinic and surrounding community of Calgary, Canada, and randomized (stratified by sex, BMI, and age) to prebiotic (oligofructose-enriched inulin; 16 g/day) or a calorie-matched placebo (maltodextrin) for 6 months. Anthropometrics, performance-based tests, knee pain, serum inflammatory markers and metabolomics, quality of life, and gut microbiota will be assessed at baseline, 3 months, 6 months (end of prebiotic supplementation), and 3 months following the end of the prebiotic supplementation. CLINICAL SIGNIFICANCE: There is growing pressure on health care systems for aggressive OA treatment such as total joint replacement. Less aggressive, yet effective, conservative treatment options have the potential to address the growing prevalence of co-morbid obesity and knee OA by delaying the need for joint replacement or ideally preventing its need altogether. The results of this clinical trial will provide the first evidence regarding the efficacy of prebiotic supplementation on knee joint function and pain in adults with obesity and knee OA. If successful, the results may provide a simple, safe, and easy to adhere to intervention to reduce knee joint pain and improve the quality of life of adults with co-morbid knee OA and obesity. TRIAL REGISTRATION: Clinical Trials.gov NCT04172688 . Registered on 21 November 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Fortuna R, Hart DA, Sharkey KA, et al. Effect of a prebiotic supplement on knee joint function, gut microbiota, and inflammation in adults with co-morbid obesity and knee osteoarthritis: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33827639. doi:10.1186/s13063-021-05212-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。